David Raben - 26 Dec 2025 Form 4 Insider Report for Bicara Therapeutics Inc. (BCAX)

Role
Chief Medical Officer
Signature
/s/ Lara Meisner, Attorney-in-Fact
Issuer symbol
BCAX
Transactions as of
26 Dec 2025
Net transactions value
+$74,996
Form type
4
Filing time
29 Dec 2025, 17:10:18 UTC
Previous filing
25 Nov 2025
Next filing
04 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Raben David Chief Medical Officer BICARA THERAPEUTICS INC., 116 HUNTINGTON AVENUE, SUITE 703, BOSTON /s/ Lara Meisner, Attorney-in-Fact 29 Dec 2025 0002034679

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCAX Common Stock Options Exercise $74,996 +19,789 +56% $3.79 55,286 26 Dec 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BCAX Stock Option (Right to Buy) Options Exercise $0 -19,789 -17% $0.000000 98,987 26 Dec 2025 Common Stock 19,789 $3.79 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This is an ISO exercise and hold to acquire and retain direct share ownership of the issuer.
F2 25% of the shares underlying this option vested on July 24, 2024, with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.